uniQure (NASDAQ:QURE) Upgraded at Cantor Fitzgerald

uniQure (NASDAQ:QURE - Get Free Report) was upgraded by equities research analysts at Cantor Fitzgerald to a "strong-buy" rating in a research report issued to clients and investors on Monday,Zacks.com reports.

A number of other analysts have also recently commented on QURE. HC Wainwright restated a "buy" rating and issued a $70.00 price target on shares of uniQure in a research report on Monday, April 21st. Chardan Capital restated a "buy" rating and issued a $38.00 price target on shares of uniQure in a research report on Monday, May 12th. Royal Bank of Canada reiterated an "outperform" rating and set a $24.00 target price on shares of uniQure in a research report on Tuesday, January 21st. StockNews.com upgraded uniQure to a "sell" rating in a research report on Tuesday, March 11th. Finally, Wells Fargo & Company cut their target price on uniQure from $35.00 to $30.00 and set an "equal weight" rating for the company in a research report on Friday, February 28th. One analyst has rated the stock with a sell rating, three have issued a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $37.82.

uniQure Stock Up 7.4%

QURE stock opened at $14.71 on Monday. The company has a debt-to-equity ratio of 0.92, a quick ratio of 6.51 and a current ratio of 6.51. The business's 50-day moving average is $12.34 and its two-hundred day moving average is $12.43. The company has a market cap of $805.75 million, a price-to-earnings ratio of -2.97 and a beta of 0.10. uniQure has a fifty-two week low of $3.73 and a fifty-two week high of $19.18.

uniQure (NASDAQ:QURE - Get Free Report) last issued its quarterly earnings results on Friday, May 9th. The biotechnology company reported ($0.82) EPS for the quarter, topping analysts' consensus estimates of ($1.07) by $0.25. The business had revenue of $1.57 million during the quarter, compared to analysts' expectations of $5.93 million. uniQure had a negative return on equity of 188.82% and a negative net margin of 837.80%. As a group, analysts forecast that uniQure will post -3.75 earnings per share for the current year.

Insider Activity

In other uniQure news, CEO Matthew C. Kapusta sold 28,341 shares of uniQure stock in a transaction on Tuesday, March 4th. The stock was sold at an average price of $10.29, for a total transaction of $291,628.89. Following the completion of the sale, the chief executive officer now directly owns 651,454 shares of the company's stock, valued at $6,703,461.66. The trade was a 4.17% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Christian Klemt sold 2,916 shares of uniQure stock in a transaction on Thursday, February 27th. The shares were sold at an average price of $11.32, for a total value of $33,009.12. Following the completion of the transaction, the chief financial officer now owns 155,168 shares in the company, valued at $1,756,501.76. This represents a 1.84% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 90,830 shares of company stock valued at $961,401 in the last ninety days. Insiders own 4.74% of the company's stock.

Institutional Trading of uniQure

Several large investors have recently added to or reduced their stakes in QURE. Avoro Capital Advisors LLC purchased a new stake in uniQure during the 4th quarter valued at about $38,410,000. Vestal Point Capital LP grew its stake in uniQure by 58.4% during the 1st quarter. Vestal Point Capital LP now owns 4,792,572 shares of the biotechnology company's stock valued at $50,801,000 after purchasing an additional 1,767,572 shares during the last quarter. RTW Investments LP grew its stake in uniQure by 8,936.3% during the 4th quarter. RTW Investments LP now owns 903,625 shares of the biotechnology company's stock valued at $15,958,000 after purchasing an additional 893,625 shares during the last quarter. Point72 Asset Management L.P. grew its stake in uniQure by 81.3% during the 4th quarter. Point72 Asset Management L.P. now owns 1,771,352 shares of the biotechnology company's stock valued at $31,282,000 after purchasing an additional 794,459 shares during the last quarter. Finally, Boxer Capital Management LLC purchased a new stake in uniQure during the 4th quarter valued at about $13,245,000. Hedge funds and other institutional investors own 78.83% of the company's stock.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.